SynthesisCurrent oncology (Toronto, Ont.)2023
Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes.
Synthesis in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Multiple Myeloma in Children and Young Adults: A Systematic Literature Review.Clinical and experimental medicine · 2026Pooled it
- Analysis of Social Drivers of Health, Race, and Ethnicity With Survival in Myeloma Patients.Clinical lymphoma, myeloma & leukemia · 2026Article
- Article
- Multiple myeloma in adolescents and young adults(AYA): global epidemiological trends, risk factors, and future projections (1990-2040).Cancer causes & control : CCC · 2026Article
- Reproductive autonomy of women living with multiple myeloma participating in a pregnancy prevention program.Reproductive health · 2025Article
- How Does Age at Diagnosis Influence Multiple Myeloma Survival? Empirical Evidence.Healthcare (Basel, Switzerland) · 2025Article
- Systematic assessment of bone and soft tissue tumors on whole-body CTs of 45 mummies from ancient Egypt.Scientific reports · 2025Article
- Multiple Myeloma Experiences and Preferences: A Mixed Methods Study of Patients and Care Partners in the United States.Patient preference and adherence · 2025Article
- Frontline management of multiple myeloma patients: optimizing treatment for patients in the Gulf region.Clinical hematology international · 2025Review
- Presentation, treatment and clinical outcomes in young multiple myeloma patients treated at a tertiary care centre in a low middle-income country.Ecancermedicalscience · 2025Article
- Clinical Characteristics, Cytogenetic Risks, and Prognoses of Young Multiple Myeloma Patients in the Era of Novel Therapies.Cancers · 2024Article
- Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study.Cancer medicine · 2024Article
- Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Normal bone marrow signal characteristics in whole-body diffusion-weighted images of amateur marathon runners.Quantitative imaging in medicine and surgery · 2024Article
- Calculated haemorheological profile and laboratory parameters in new diagnosed multiple myeloma patients: retrospective analysis according to survival.Therapeutic advances in hematology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple myeloma usually affects older adults. However, younger patients constitute a significant subset as approximately 10% of cases occur in subjects younger than 50 years old. Young patients, who are underrepresented in the literature, are diagnosed during their most productive years of life, urging the need for tailored treatment approaches. This literature review aims to report recent studies specifically addressing young patients with a focus on characteristics at diagnosis, cytogenetics, treatments, and outcomes. We searched PubMed for studies involving young patients with multiple myeloma ≤50 years old. The time span of our literature review search was from 1 January 2010 to 31 December 2022. Overall, 16 retrospective studies were analyzed for this review. Young patients with multiple myeloma tend to have less advanced disease, more frequent light chain subtypes, and survive longer compared to their older counterparts. However, available studies included a limited number of patients; the newest revised international staging system was not used to stratify patients, cytogenetics varied from one cohort to another, and most patients did not receive contemporary triplet/quadruplet treatments. This review emphasizes the need to perform contemporary, large-scale retrospective studies to improve knowledge regarding the presentation and outcomes of young myeloma patients in the era of modern treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.